EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Primary Sclerosing Cholangitis Worsens Prognosis in Patients With Inflammatory Bowel Disease: A Propensity‐Matched Cohort Study

Ferdinando D'Amico iD, Mariangela Allocca, Francesca Lusetti, Tommaso Lorenzo Parigi, Francesca Rusconi, Gema Hernandez, Alba Segovia-Hilara, Virginia Solitano, Alessandra Zilli, Federica Furfaro, Gionata Fiorino iD, Pietro Invernizzi und 3 weitere

United European Gastroenterology Journal · 2025

DOI: 10.1002/ueg2.70058 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift United European Gastroenterology Journal, 2025. Verfasst von Ferdinando D'Amico und 14 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita Salute San Raffaele University, Milan, Italy. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing, Colitis, Ulcerative, Crohn Disease, Inflammatory Bowel Diseases. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Few data are available on the impact of primary sclerosing cholangitis (PSC) on inflammatory bowel disease (IBD).

Objective

We conducted a retrospective study using TriNetX to compare the outcomes of patients with IBD and those with concomitant IBD and PSC.

Methods

All patients with a confirmed diagnosis of Crohn's disease (CD), ulcerative colitis (UC), or indeterminate colitis with or without PSC were eligible. One‐to‐one propensity score matching was employed to balance demographic parameters, comorbid conditions, and IBD medications between cohort 1 (IBD) and cohort 2 (IBD and concomitant PSC). The primary endpoint was a composite endpoint including the risk of mortality, hospitalization, and surgery. Risks were expressed as Hazard Ratio (HR) with a 95% confidence interval (CI).

Results

A total of 398,980 IBD patients were analyzed (cohort 1: 395,874 and cohort 2: 3106). After propensity‐score‐matching, 3007 patients from each group were included (mean age 48.1 ± 19.4 years, female 40%, UC 75% CD 24.8%). Approximately 1%–2% of patients were treated with advanced therapies. Cohort 2 patients had a higher risk of experiencing the composite endpoint compared to cohort 1 group (HR:1.32, 95%CI:1.23−1.42). Similarly, a higher risk of hospitalization and mortality was identified in subjects with IBD and concomitant PSC (HR:1.32, 95% CI: 1.22−1.43 and HR: 1.69, 95%CI: 1.46−1.96). Both CD and UC patients with concomitant PSC had a higher risk of achieving the composite endpoint (HR: 1.18, 95%CI: 1.02−1.37 and HR: 1.29, 95%CI: 1.18−1.40). An increased risk of mortality and hospitalization was found both in patients with CD (HR: 2.16, 95%CI:1.58−2.95, and 1.20, 95%CI:1.03−1.41) and UC (HR: 1.87, 95%CI: 1.57−2.22 and HR: 1.27, 95%CI:1.16−1.40) and concomitant PSC.

Conclusion

In this administrative study of patients with IBD and PSC, concomitant PSC was associated with an increased risk of mortality and hospitalization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholangitis, SclerosingColitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesHumansFemaleMaleMiddle AgedPropensity ScoreRetrospective StudiesAdultPrognosisHospitalization

Stichwörter der Autor:innen

Crohn's diseasehospitalization riskinflammatory bowel diseasemortality riskprimary sclerosing cholangitispropensity score matchingulcerative colitis

Autor:innen und Institutionen

  • Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita Salute San Raffaele University, Milan, Italy.
  • Gastroenterology Unit, Foundation Policlinico San Matteo IRCCS, University of Pavia, Pavia, Italy.
  • TriNetX Europe NV, Sint-Martens-Latem, Belgium.
  • Departamento de Inteligencia Artificial, Biomedical Informatics Group, ETSI Informaticos, Universidad Politecnica de Madrid, Madrid, Spain.
  • Division of Gastroenterology, Western University, London, Canada.
  • IBD Unit, San Camillo-Forlanini Hospital, Rome, Italy.

ORCID-Profile: Ferdinando D'Amico, Gionata Fiorino, Laurent Peyrin-Biroulet, Vipul Jairath, Silvio Danese

Zitieren

APA

D'Amico, F., Allocca, M., Lusetti, F., Parigi, T. L., Rusconi, F., Hernandez, G., Segovia-Hilara, A., Solitano, V., Zilli, A., Furfaro, F., Fiorino, G., Invernizzi, P., Peyrin-Biroulet, L., Jairath, V., & Danese, S. (2025). Primary Sclerosing Cholangitis Worsens Prognosis in Patients With Inflammatory Bowel Disease: A Propensity‐Matched Cohort Study. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.70058

Vancouver

D'Amico F, Allocca M, Lusetti F, Parigi TL, Rusconi F, Hernandez G, et al. Primary Sclerosing Cholangitis Worsens Prognosis in Patients With Inflammatory Bowel Disease: A Propensity‐Matched Cohort Study. United European Gastroenterology Journal. 2025. doi:10.1002/ueg2.70058

BibTeX
@article{DAmico2025,
  author = {D'Amico, Ferdinando and Allocca, Mariangela and Lusetti, Francesca and Parigi, Tommaso Lorenzo and Rusconi, Francesca and Hernandez, Gema and Segovia-Hilara, Alba and Solitano, Virginia and Zilli, Alessandra and Furfaro, Federica and Fiorino, Gionata and Invernizzi, Pietro and Peyrin-Biroulet, Laurent and Jairath, Vipul and Danese, Silvio},
  title = {Primary Sclerosing Cholangitis Worsens Prognosis in Patients With Inflammatory Bowel Disease: A Propensity‐Matched Cohort Study},
  journal = {United European Gastroenterology Journal},
  year = {2025},
  doi = {10.1002/ueg2.70058}
}
Kostenlos starten →